ClinicalTrials.gg
Active, not recruitingNCT02773030Updated Mar 20, 2026Results posted

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

A Phase 1/2 interventional study of CC-220 and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Active, not recruiting at 162 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing iberdomide in Multiple Myeloma — 11 open to participants now, 24 under way, 3 of them phase 3. iberdomide · Multiple Myeloma.

Enrollment
4th of 27
466 · median 75
Started
2016
the only one that year
Phase 1/2
8 of 27
3 open now
Primary completion
2024-05
later than 1 of 23 live
Registered
1st of 27
by date
Lead sponsor
2 of 27
Celgene

Among the 27 studies testing iberdomide in Multiple Myeloma, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 8 in phase 1/2, reaches primary completion later than 1 of the 23 other live ones, and was the 1st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

11 of the 27 studies testing iberdomide in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About iberdomide

iberdomide: first FDA approval 2026 (ZENBEXUS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing iberdomide in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Read the detailed description

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has been determined to be safe. Progressive disease must be confirmed in accordance with international myeloma working group (IMWG) criteria.

The starting dose of DEX will be 40 mg for subjects who are ≤75 years of age and 20 mg for subjects who are >75 years of age, given once weekly. This treatment will continue until PD, unacceptable toxicity or the subject withdraws consent.

For Cohorts A and B, the starting dose level of CC-220, dose level 1, is 0.3 mg. A dose level -1, of 0.15 mg, may also be evaluated if the starting dose level of 0.3 mg for 21 days of a 28-day cycle is not tolerated. For Cohorts E and F, the starting dose level of CC-220, dose level 1, is one dose level below the maximum dose for Cohort B that has been determined to be safe by the dose escalation committee (DEC) at the start of enrollment for both cohorts. For Cohort E in addition to CC-220 and DEX, daratumumab will be administered intravenously (IV) at a 16mg/kg dose. For Cohort F in addition to CC-220 and DEX, bortezomib will be administered subcutaneous (SC) at a 1.3mg/m2 dose.

All subjects with a minimal response (MR) or better who discontinue study treatment in Part 1 or Part 2 of the study for a reason other than PD or withdrawal of consent from the study will be followed for response assessment every 28 days (every 21 days for Cohort F) until PD.

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

The initiation of Part 2 will begin when the RP2D is established in Part 1 in either Cohort A or Cohort B. Either cohort may begin once the RP2D is determined for each cohort independently during Part 1. All expansion decisions will be determined by the DEC after review of all safety, PK, biomarker and preliminary efficacy data, as applicable. During Part 2, the Independent Expert Reviewer will review safety data and any other data deemed relevant so that subject safety is ensured.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Relapsed
  • Refractory
  • Pharmacokinetics
  • Safety
  • Efficacy
  • CC-220
  • Relapsed and refractory multiple myeloma
  • Dexamethasone
  • Daratumumab
  • Bortezomib
  • Newly diagnosed multiple myeloma
  • Newly diagnosed multiple myeloma transplant non-eligible
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. All subjects in RRMM cohorts must have a documented diagnosis of Multiple Myeloma and have defined as:

  1. M-protein (serum and/or urine protein electrophoresis (sPEP or uPEP)): sPEP ≥0.5 g/dL or uPEP ≥200 mg/24 hours and/or
  2. Light chain Multiple Myeloma without measurable disease in the serum or urine: serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio 2. All subjects in RRMM cohorts must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy. Subjects who had CAR T therapy as their last myeloma therapy must have documented disease progression.

    3. (ECOG) performance status score of 0, 1 or 2 3. Subject must have documented diagnosis with previously untreated symptomatic MM as defined by the criteria below (Rajkumar, 2016): MM diagnostic criteria;

    - Clonal bone marrow plasma cells ≥ 10% or -proven bony or extramedullary plasmacytoma

    - Any one or more of the following myeloma defining events:

    • One or more of the following myeloma-related organ dysfunction (at least one of the following);

      • [C] Calcium elevation (serum calcium > 0.25 mmol/L [> 1 mg/dL] higher than the upper limit of laboratory normal or > 2.75 mmol/L [> 11 mg/dL])
      • [R] Renal insufficiency (serum creatinine > 2 mg/dl [> 177 μmol/L] or \< 40 ml/min)
      • [A] Anemia ( \< 10 g/dl or > 2 g/dL below the lower limit of laboratory normal)
      • [B] Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)/CT
    • One or more of the following biomarkers of :

      • Clonal bone marrow plasma cell percentage* ≥ 60%
      • Abnormal serum free light-chain (FLC) ratio ≥ 100 (involved kappa) or \<0.01 (involved lambda) and involved FLC level must be ≥ 100 mg/L
      • >1 focal lesion detected by magnetic resonance imaging (MRI) (at least 5 mm in size)

    AND have measurable disease, as assessed by central laboratory, defined by any of the following:

    - Immunoglobulin (Ig)G myeloma: serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 hours; or

    - IgA, IgM, IgD, or IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or

    - Light chain multiple myeloma without measurable disease in serum or urine: serum FLC ≥ 100 mg/L and abnormal kappa lambda (κ/λ) ratio 4. Subjects in Cohort J1 are not considered by the investigator as eligible for high-dose chemotherapy and stem cell transplantation due to:

    - Age ≥65 years, OR

    - In subjects \<65 years: presence of important comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with autologous stem cell transplantation.

    5. Subjects in Cohort J2 are considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation according to the institution's criteria based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid condition(s), physical examination, and laboratory data.

Exclusion criteria

Exclusion Criteria:

1. Subject has nonsecretory multiple myeloma 2. Subjects with Plasma Cell leukemia or amyloidosis 3. Any of the following laboratory abnormalities

  • (ANC) \<1,000/μL
  • count \< 75,000/μL for Part 1. For Part 2; platelet count \< 75,000/μL for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells; otherwise platelet count \< 50,000/μL (transfusions are not permitted to achieve minimum platelet counts
  • Corrected serum calcium >13.5 mg/dL (>3.4 mmol/L)
  • Serum glutamic oxaloacetic transaminase ()/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)≥2.0 x (ULN)
  • Serum total and alkaline phosphatase >1.5 x ULN
  • Subjects with serious renal impairment ([CrCl] \<45 mL/min) or requiring dialysis would be excluded 4. Subjects with peripheral neuropathy ≥Grade 2
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
466 participants (actual)

Study arms

  • Experimental
    Cohort A: CC-220 Monotherapy - Part 1

    Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle

    Drug: CC-220

  • Experimental
    Cohort B: CC-220 in combination with Dexamethasone - Part 1

    * Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. * For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment.

    Drug: CC-220 · Drug: Dexamethasone

  • Experimental
    Cohort D: CC-220 in combination with Dexamethasone - Part 2

    * Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle * Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.

    Drug: CC-220 · Drug: Dexamethasone

  • Experimental
    Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1

    * Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. * Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. * Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle. Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA. * Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. * Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. * Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.

    Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Daratumumab - 16mg/kg · Drug: Daratumumab- 1800mg

  • Experimental
    Cohort F: CC-220 with DEX and bortezomib - Part 1

    * Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle. * Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle. * Subcutaneous BTZ at dose 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.

    Drug: CC-220 · Drug: Dexamethasone · Drug: Bortezomib · Drug: Bortezomib (BTZ)

  • Experimental
    Cohort G1-CC-220 in combination with CFZ and DEX -Part 1

    * Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle * Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle * Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects \> 75 years old, the DEX dose will be 20 mg

    Drug: CC-220 · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1

    * Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle * Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle * Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg

    Drug: CC-220 · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2

    * Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle * Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.

    Drug: CC-220 · Drug: Dexamethasone

  • Experimental
    CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2

    * Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above). * Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (\> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle. * Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle.

    Drug: CC-220 · Drug: Dexamethasone · Drug: Bortezomib · Drug: Bortezomib (BTZ)

  • Experimental
    CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2

    * Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle. * Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (\> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle. * Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle.

    Drug: CC-220 · Drug: Dexamethasone · Drug: Bortezomib · Drug: Bortezomib (BTZ)

  • Experimental
    Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible - Part 2

    Oral CC-220 at 1.0mg, 1.3mg or 1.6mg from Days 1-21 of each 28-day cycle. Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. Subcutaneous DARA at 1800 mg over 3 to 5minutes on Days 1, 8, 15, and 22 at cycle 1-2 of a 28-day cycle, Days1, and 15 at cycle 3-6 of a 28-day cycle, and Day1 at cycle ≥7 of each 28-day cycle.

    Drug: Daratumumab

Interventions

  • DrugCC-220

    CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.

    Also known as: Iberdomide

  • Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.

    Also known as: Decadron

  • Specified dose on specified days

    Also known as: Darzalex

  • Specified dose on specified days

    Also known as: Velcade

  • Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.

    Also known as: Kyprolis

  • DrugDaratumumab - 16mg/kg

    Drug page: Daratumumab

    Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.

    Also known as: Darzalex

  • Bortezomib 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.

    Also known as: Velcade

  • Daratumumab (DARA) 1800 mg by subcutaneous injection on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.

    Also known as: Darzalex Faspro

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities in Part 1.

    The dose-limiting toxicity (DLT) population includes subjects who missed no more than 4 doses of CC-220, 2 doses of DEX, 1 dose of IV DARA (Cohort E), 1 dose of BTZ (Cohort F), or 1 dose of CFZ (Cohort G1 or G2) during Cycle 1 for reasons other than DLT. This population will be used for analyzing the primary endpoint regarding the determination of the MTD. Hematologic DLTs: Grade 4 neutropenia (ANC \<500/μL for \>5 days) Grade 3 neutropenia (ANC \<1,000/μL) with fever ≥38.5°C Grade 4 thrombocytopenia (platelet count \<25,000/μL) or Grade 3 thrombocytopenia with bleeding or need for platelet transfusion Any other grade 4 hematologic toxicity, except anemia, not resolving to pretreatment baseline within 72 hours. Non-hematologic DLT: Any non-hematological toxicity ≥ Grade 3, except alopecia and nausea controlled by medical management.

    Time frame: From first dose to 28 days post last dose (up to 28 days)

  2. Overall Response Rate (ORR) in Cohort D and Cohort H2

    Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.

    Time frame: Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)

Secondary outcomes

  1. Number of Participants With Treatment Related Adverse Events

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

    Time frame: Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months

  2. Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESI)

    An adverse event of special interest (AESI) is one of scientific and medical interest specific to understanding the safety profile of the Investigational Product, CC-220, and may require close monitoring and rapid communication by the Investigator to the Sponsor. An AESI may be serious or nonserious. The rapid reporting of AESIs allows ongoing surveillance of these events in order to characterize and understand their association with the use of this investigational product.

    Time frame: Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months

  3. Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K

    The very good partial response or better (≥ VGPR) rate is defined as the proportion of subjects with best response of VGPR or better during the trial without administration of myeloma therapy other than study treatment. The ≥ VGPR rate with 95% confidence interval (CI) together with the proportions in each response category based on the IMWG Uniform Response Criteria.

    Time frame: On Average of (Cohort J: 86.21, Cohort K: 56.29) Weeks

  4. Overall Response Rate (ORR)

    Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.

    Time frame: On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks

  5. Time to Response (TTR)

    Time to response is defined as the time from the first dose date of study treatment to the first date of documented response (PR or better). Time to response will be summarized for responders using descriptive statistics by cohort and dose level.

    Time frame: On Average of (Cohort A:19.14, Cohort B: 12.39, Cohort D: 7.54, Cohort E: 5.44, Cohort F: 4.97, Cohort G: 12.30, Cohort H: 4.14, Cohort I: 8.79, Cohort J: 4.76, Cohort K: 6.51) Weeks

  6. Duration of Response

    Duration of response is defined as time from the earliest date of documented response (PR or better) to the earliest date of disease progression per IMWG Uniform Response Criteria or death, whichever occurred first. Participants who do not have progression of disease or death will be censored on the last adequate response assessment date. Duration of response for responders will be summarized using Kaplan-Meier estimates by cohort and dose level as appropriate. Data will be collected and analyzed per Cohort Totals.

    Time frame: On Average of (Cohort A:161.33, Cohort B: 63.74, Cohort D: 39.16, Cohort E: 89.56, Cohort F: 69.24, Cohort G: 80.93, Cohort H1: 77.11, Cohort H2: 42.71, Cohort I: 36.80, Cohort J: 92.36, Cohort K: 51.85) Weeks

  7. Progression Free Survival

    Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first Data will be collected and analyzed per Cohort Totals.

    Time frame: On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks

  8. Overall Survival for Cohort D, Cohort H2 and Cohort I

    Time from first dose of IP to death due to any cause Data will be collected and analyzed per Cohort Totals.

    Time frame: On Average of (Cohort D: 81.14 Cohort H2: 91.54 Cohort I: 74.20)Weeks

  9. Auc(Tau)

    Area under the plasma concentration time-curve. AUC over the dosing interval.

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)

  10. Cmax

    Cmax is defined as maximum plasma concentration of the drug.

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)

  11. Tmax

    Tmax is defined is the time to maximum plasma concentration.

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)

07

Results

Posted Mar 20, 2026
Limitations and caveats
Endpoints 8-10 were analyzed by cohort, not treatment (see protocol 9.6.3). Participant mortality in the flow differs from adverse events due to different collection periods: flow captures mortality until primary database lock, while adverse events track until study completion. Refer to the protocol for details. Any discrepancies in data between the two fields is due to data being cleaned and corrected.

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Started33466710333131310814131073351326371094846541117252525
Completed10000000000000010001140100112100110222020
Not completed2346671033313131081412107334122236109372554107355
Post Response Follow Up Period
Participant flow — Post Response Follow Up Period
MilestoneCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Started33466710333131310814131073351326371094846541117252525
Completed223456932311101067823241115158434150401010
Not completed111211101023027510501121122251431537116252425
Withdrew: Death000100100012012278000030100010032401122
Withdrew: Progressive disease0000000000000010200000001202100000000
Withdrew: Withdrawal by subject0011000000010021501014200100000302011
Withdrew: Lost to follow-up0000010000000001000000000100000100000
Withdrew: Other reasons0100100010100120000000001000000001100
Withdrew: Still on-going100000000000000120001140100112129112222122
Withdrew: Adverse event0000000000000000000000000100000000000
Withdrew: Physician decision0000000000000000000000000000000000100

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities in Part 1.

The dose-limiting toxicity (DLT) population includes subjects who missed no more than 4 doses of CC-220, 2 doses of DEX, 1 dose of IV DARA (Cohort E), 1 dose of BTZ (Cohort F), or 1 dose of CFZ (Cohort G1 or G2) during Cycle 1 for reasons other than DLT. This population will be used for analyzing the primary endpoint regarding the determination of the MTD. Hematologic DLTs: Grade 4 neutropenia (ANC \<500/μL for \>5 days) Grade 3 neutropenia (ANC \<1,000/μL) with fever ≥38.5°C Grade 4 thrombocytopenia (platelet count \<25,000/μL) or Grade 3 thrombocytopenia with bleeding or need for platelet transfusion Any other grade 4 hematologic toxicity, except anemia, not resolving to pretreatment baseline within 72 hours. Non-hematologic DLT: Any non-hematological toxicity ≥ Grade 3, except alopecia and nausea controlled by medical management.

Time frame:
From first dose to 28 days post last dose (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities in Part 1.
ParticipantsCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Number of Participants With Dose Limiting Toxicities in Part 1.0001110000000110——————01010111———————
PrimaryOverall Response Rate (ORR) in Cohort D and Cohort H2

Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.

Time frame:
Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) in Cohort D and Cohort H2
Percentage of ParticipantsCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Overall Response Rate (ORR) in Cohort D and Cohort H2————————————————26.2 (18.1 to 35.6)—————————————20.0 (0.5 to 71.6)——————
SecondaryNumber of Participants With Treatment Related Adverse Events

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

Time frame:
Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events
ParticipantsCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Number of Participants With Treatment Related Adverse Events233667832391087131195035122337784646530115242423
SecondaryNumber of Participants With Treatment Emergent Adverse Events of Special Interest (AESI)

An adverse event of special interest (AESI) is one of scientific and medical interest specific to understanding the safety profile of the Investigational Product, CC-220, and may require close monitoring and rapid communication by the Investigator to the Sponsor. An AESI may be serious or nonserious. The rapid reporting of AESIs allows ongoing surveillance of these events in order to characterize and understand their association with the use of this investigational product.

Time frame:
Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESI)
ParticipantsCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESI)10010111000000109000120013101———04200
SecondaryVery Good Partial Response Rate (ORR) in Cohort J1 and Cohort K

The very good partial response or better (≥ VGPR) rate is defined as the proportion of subjects with best response of VGPR or better during the trial without administration of myeloma therapy other than study treatment. The ≥ VGPR rate with 95% confidence interval (CI) together with the proportions in each response category based on the IMWG Uniform Response Criteria.

Time frame:
On Average of (Cohort J: 86.21, Cohort K: 56.29) Weeks
Reported as:
Number · Percentage of Participants
Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K
Percentage of ParticipantsCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Very Good Partial Response Rate (ORR) in Cohort J1 and Cohort K————————————————————————————————100.0 (2.5 to 100.0)82.4 (56.6 to 96.2)72.0 (50.6 to 87.9)100.00 (86.3 to 100.0)88.0 (68.8 to 97.5)
SecondaryOverall Response Rate (ORR)

Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.

Time frame:
On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Overall Response Rate (ORR)0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 60.2)33.3 (4.3 to 77.7)0 (0.0 to 45.9)14.3 (0.4 to 57.9)30.0 (6.7 to 65.2)33.3 (0.8 to 90.6)33.3 (0.8 to 90.6)66.7 (9.4 to 99.2)30.8 (9.1 to 61.4)23.1 (5.0 to 53.8)20.0 (2.5 to 55.6)25.0 (3.2 to 65.1)50.0 (23.0 to 77.0)30.8 (9.1 to 61.4)26.2 (18.1 to 35.6)0 (0.0 to 70.8)33.3 (0.8 to 90.6)20.0 (0.5 to 71.6)61.5 (31.6 to 86.1)53.8 (33.4 to 73.4)33.3 (0.8 to 90.6)42.9 (9.9 to 81.6)70.0 (34.8 to 93.3)66.7 (29.9 to 92.5)75.0 (19.4 to 99.4)50.0 (15.7 to 84.3)75.0 (19.4 to 99.4)66.7 (22.3 to 95.7)20.0 (0.5 to 71.6)34.1 (20.1 to 50.6)100.0 (2.5 to 100.0)82.4 (56.6 to 96.2)96.0 (79.6 to 99.9)100.0 (86.3 to 100.0)88.0 (68.8 to 97.5)
SecondaryTime to Response (TTR)

Time to response is defined as the time from the first dose date of study treatment to the first date of documented response (PR or better). Time to response will be summarized for responders using descriptive statistics by cohort and dose level.

Time frame:
On Average of (Cohort A:19.14, Cohort B: 12.39, Cohort D: 7.54, Cohort E: 5.44, Cohort F: 4.97, Cohort G: 12.30, Cohort H: 4.14, Cohort I: 8.79, Cohort J: 4.76, Cohort K: 6.51) Weeks
Reported as:
Median · Weeks
Time to Response (TTR)
WeeksCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
Time to Response (TTR)———24.64 (8.1 to 41.1)—8.14 (8.14 to 8.14)7.86 (5.7 to 8.1)56.0 (56.0 to 56.0)8.14 (8.14 to 8.14)33.14 (10.1 to 56.1)4.14 (4.1 to 8.3)7.14 (4.1 to 16.1)12.14 (4.1 to 20.1)10.21 (8.4 to 12.0)8.14 (4.1 to 20.4)8.07 (4.3 to 12.1)4.21 (3.9 to 19.9)—4.14 (4.14 to 4.14)7.86 (7.86 to 7.86)4.14 (4.1 to 12.0)4.14 (4.0 to 13.1)6.14 (6.14 to 6.14)3.14 (3.1 to 13.1)3.71 (3.1 to 9.1)3.36 (3.0 to 7.3)4.14 (4.1 to 8.1)8.14 (4.0 to 62.1)8.86 (4.1 to 11.1)6.14 (4.1 to 8.3)4.14 (4.14 to 4.14)6.29 (4.1 to 23.3)3.14 (3.14 to 3.14)3.14 (3.0 to 17.0)5.07 (4.0 to 49.0)4.14 (4.0 to 25.1)4.14 (4.0 to 9.3)
SecondaryDuration of Response

Duration of response is defined as time from the earliest date of documented response (PR or better) to the earliest date of disease progression per IMWG Uniform Response Criteria or death, whichever occurred first. Participants who do not have progression of disease or death will be censored on the last adequate response assessment date. Duration of response for responders will be summarized using Kaplan-Meier estimates by cohort and dose level as appropriate. Data will be collected and analyzed per Cohort Totals.

Time frame:
On Average of (Cohort A:161.33, Cohort B: 63.74, Cohort D: 39.16, Cohort E: 89.56, Cohort F: 69.24, Cohort G: 80.93, Cohort H1: 77.11, Cohort H2: 42.71, Cohort I: 36.80, Cohort J: 92.36, Cohort K: 51.85) Weeks
Reported as:
Median · Weeks
Duration of Response
WeeksCohort A: TotalCohort B: TotalCohort D: TotalCohort E: TotalCohort F: TotalCohort G: TotalCohort H1Cohort H2Cohort ICohort J: TotalCohort K
Duration of Response176.14 (40.7 to 267.1)45.00 (7.4 to 239.3)28.64 (2.9 to 146.1)59.21 (9.1 to 265.1)69.29 (6.6 to 255.1)66.64 (22.7 to 238.3)43.57 (12.1 to 209.1)42.71 (42.71 to 42.71)32.79 (8.0 to 80.1)104.71 (17.0 to 123.1)52.14 (21.0 to 77.3)
SecondaryProgression Free Survival

Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first Data will be collected and analyzed per Cohort Totals.

Time frame:
On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks
Reported as:
Median · Weeks
Progression Free Survival
WeeksCohort A: TotalCohort B: TotalCohort D: TotalCohort E: TotalCohort F: TotalCohort G: TotalCohort H1Cohort H2Cohort ICohort J: TotalCohort K
Progression Free Survival12.29 (0.1 to 395.0)14.71 (0.1 to 247.0)12.14 (0.1 to 150.1)20.71 (2.1 to 269.1)15.14 (0.1 to 258.1)48.57 (4.1 to 246.3)26.14 (5.3 to 213.1)22.14 (8.3 to 46.7)10.14 (0.1 to 84.4)107.00 (0.1 to 127.9)57.14 (0.1 to 81.3)
SecondaryOverall Survival for Cohort D, Cohort H2 and Cohort I

Time from first dose of IP to death due to any cause Data will be collected and analyzed per Cohort Totals.

Time frame:
On Average of (Cohort D: 81.14 Cohort H2: 91.54 Cohort I: 74.20)Weeks
Reported as:
Median · Weeks
Overall Survival for Cohort D, Cohort H2 and Cohort I
WeeksCohort D: TotalCohort H2Cohort I
Overall Survival for Cohort D, Cohort H2 and Cohort I44.29 (1.9 to 228.0)103.43 (19.9 to 147.0)60.43 (6.6 to 210.6)
SecondaryAuc(Tau)

Area under the plasma concentration time-curve. AUC over the dosing interval.

Time frame:
From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
Reported as:
Geometric mean · hr*ng/mL
Auc(Tau)
hr*ng/mLCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
CC-220—22.5946 ± 3.2396111.1790 ± NA66.0413 ± 11.0851——20.1061 ± NA—57.9410 ± NA—119.8230 ± 165.655345.7555 ± 12.306096.1991 ± 97.345284.8140 ± NA101.8990 ± NA118.5940 ± NA181.3199 ± 55.838014.5430 ± NA————18.3610 ± NA——————196.8304 ± 92.5871———————
CC-17195——5.0220 ± NA———————7.2409 ± 67.0218—11.5310 ± NA5.8280 ± NA5.7470 ± NA—10.7279 ± 51.1651————————————20.1595 ± 72.6176———————
SecondaryCmax

Cmax is defined as maximum plasma concentration of the drug.

Time frame:
From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
Reported as:
Geometric mean · ng/mL
Cmax
ng/mLCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
CC-2201.5200 ± NA1.7944 ± 15.428710.7000 ± NA5.5929 ± 28.1747——1.7600 ± NA—4.7800 ± NA—9.9124 ± 267.28013.5017 ± 64.51118.2704 ± 172.89697.5100 ± NA9.9200 ± NA7.4627 ± 32.875612.1183 ± 39.80832.5200 ± NA13.0000 ± NA13.9000 ± NA6.6900 ± NA—1.3300 ± NA—19.8000 ± NA—5.1600 ± NA6.4300 ± NA—15.3411 ± 79.6863———————
CC-17195——0.2980 ± NA0.1501 ± 9.9068————0.2240 ± NA—0.4188 ± 103.58400.1610 ± NA0.3475 ± 104.88250.3480 ± NA0.3550 ± NA0.3588 ± 30.81490.5330 ± 51.5168—0.3050 ± NA0.6700————0.7240—0.2430 ± NA0.2900 ± NA—0.9957 ± 60.6459———————
SecondaryTmax

Tmax is defined is the time to maximum plasma concentration.

Time frame:
From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
Reported as:
Median · Hours
Tmax
HoursCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
CC-2203.0000 (3.0000 to 3.0000)3.5585 (3.000 to 4.117)1.0000 (1.0000 to 1.0000)1.9415 (1.933 to 1.950)——3.0000 (3.0000 to 3.0000)—3.0000 (3.0000 to 3.0000)—2.0085 (1.000 to 3.017)2.9580 (1.933 to 3.983)2.4915 (2.000 to 2.983)2.0170 (2.0170 to 2.0170)3.0000 (3.0000 to 3.0000)2.9165 (2.833 to 3.000)2.0000 (2.0000 to 5.017)3.850 (3.850 to 3.850)1.000 (1.000 to 1.000)2.000 (2.000 to 2.000)2.000 (2.000 to 2.000)—5.50 (5.50 to 5.50)—2.00 (2.00 to 2.00)—1.8830 (1.8830 to 1.8830)3.6670 (3.6670 to 6.6670)—3.9000 (1.900 to 5.783)———————
CC-17195——1.0000 (1.0000 to 1.0000)3.4500 (0.967 to 5.933)————2.000 (2.000 to 2.000)—4.9835 (2.050 to 7.917)2.9830 (2.9830 to 2.9830)3.5085 (3.000 to 4.017)1.0170 (1.0170 to 1.0170)3.0000 (3.000 to 3.000)5.4165 (2.833 to 8.000)5.0000 (2.000 to 5.0000)—1.000 (1.000 to 1.000)2.000 (2.000 to 2.000)————4.00 (4.00 to 4.00)—7.1000 (7.1000 to 7.1000)3.6670 (3.6670 to 3.6670)—6.7415 (1.900 to 8.133)———————

Adverse events

Collected over Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Treatment 10/3 (0%)2/3 (66.7%)3/3 (100%)
Cohort A: Treatment 20/3 (0%)1/3 (33.3%)3/3 (100%)
Cohort A: Treatment 30/4 (0%)2/4 (50%)4/4 (100%)
Cohort A: Treatment 41/6 (16.7%)3/6 (50%)6/6 (100%)
Cohort A: Treatment 50/6 (0%)2/6 (33.3%)6/6 (100%)
Cohort A: Treatment 60/7 (0%)3/7 (42.9%)7/7 (100%)
Cohort B: Treatment 11/10 (10%)5/10 (50%)10/10 (100%)
Cohort B: Treatment 20/3 (0%)1/3 (33.3%)3/3 (100%)
Cohort B: Treatment 30/3 (0%)0/3 (0%)3/3 (100%)
Cohort B: Treatment 40/3 (0%)2/3 (66.7%)3/3 (100%)
Cohort B: Treatment 51/13 (7.7%)8/13 (61.5%)13/13 (100%)
Cohort B: Treatment 62/13 (15.4%)8/13 (61.5%)13/13 (100%)
Cohort B: Treatment 70/10 (0%)5/10 (50%)10/10 (100%)
Cohort B: Treatment 82/8 (25%)5/8 (62.5%)7/8 (87.5%)
Cohort B: Treatment 92/14 (14.3%)9/14 (64.3%)13/14 (92.9%)
Cohort B: Treatment 102/13 (15.4%)6/13 (46.2%)13/13 (100%)
Cohort D: Treatment 182/107 (76.6%)61/107 (57%)106/107 (99.1%)
Cohort E: Treatment 10/3 (0%)1/3 (33.3%)3/3 (100%)
Cohort E: Treatment 20/3 (0%)2/3 (66.7%)3/3 (100%)
Cohort E: Treatment 30/5 (0%)3/5 (60%)5/5 (100%)
Cohort E: Treatment 41/13 (7.7%)5/13 (38.5%)13/13 (100%)
Cohort E: Treatment 54/26 (15.4%)11/26 (42.3%)26/26 (100%)
Cohort F: Treatment 10/3 (0%)0/3 (0%)3/3 (100%)
Cohort F: Treatment 21/7 (14.3%)4/7 (57.1%)7/7 (100%)
Cohort F: Treatment 30/10 (0%)3/10 (30%)10/10 (100%)
Cohort F: Treatment 40/9 (0%)6/9 (66.7%)8/9 (88.9%)
Cohort G: Treatment 10/4 (0%)3/4 (75%)4/4 (100%)
Cohort G: Treatment 21/8 (12.5%)5/8 (62.5%)7/8 (87.5%)
Cohort G: Treatment 31/4 (25%)4/4 (100%)4/4 (100%)
Cohort H10/6 (0%)3/6 (50%)6/6 (100%)
Cohort H23/5 (60%)1/5 (20%)5/5 (100%)
Cohort I27/41 (65.9%)17/41 (41.5%)39/41 (95.1%)
Cohort J1: Treatment 10/1 (0%)0/1 (0%)1/1 (100%)
Cohort J1: Treatment 21/16 (6.3%)12/16 (75%)16/16 (100%)
Cohort J: Doseage Unknown0/1 (0%)0/1 (0%)1/1 (100%)
Cohort K: Treatment 11/25 (4%)13/25 (52%)24/25 (96%)
Cohort K: Treatment 22/25 (8%)11/25 (44%)25/25 (100%)
Cohort K: Treatment 32/25 (8%)15/25 (60%)25/25 (100%)
Most frequent serious events
Showing 10 of 196
Most frequent serious events
EventCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort J: Doseage UnknownCohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
BronchitisInfections and infestations0/30/30/40/60/60/70/101/30/30/30/130/130/100/81/140/130/1070/30/30/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
CellulitisInfections and infestations0/30/30/40/60/61/70/100/30/30/30/130/130/100/80/140/131/1070/31/30/51/130/260/30/70/100/90/40/80/40/60/50/410/11/160/10/250/250/25
ChorioretinitisInfections and infestations1/30/30/40/60/60/70/100/30/30/30/130/130/100/80/140/130/1070/30/30/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
Clostridium difficile colitisInfections and infestations1/30/30/40/60/60/70/100/30/30/30/130/130/100/80/140/130/1070/30/30/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
Cytomegalovirus chorioretinitisInfections and infestations1/30/30/40/60/60/70/100/30/30/30/130/130/100/80/140/130/1070/30/30/50/131/260/30/70/100/90/40/80/40/60/50/410/10/160/10/251/250/25
Device related infectionInfections and infestations0/30/30/40/60/60/70/101/30/30/30/130/130/100/80/140/130/1070/30/30/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
Gastroenteritis rotavirusInfections and infestations0/30/30/40/60/60/70/100/30/31/30/130/130/100/80/140/130/1070/30/30/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
Lower respiratory tract infectionInfections and infestations0/31/30/41/61/60/71/100/30/30/30/130/130/101/80/140/130/1070/30/31/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
Lower respiratory tract infection viralInfections and infestations0/30/30/40/60/60/70/100/30/31/30/130/130/100/80/140/130/1070/30/30/50/130/260/30/70/100/90/40/80/40/60/50/410/10/160/10/250/250/25
Pneumocystis jirovecii pneumoniaInfections and infestations0/30/30/40/60/60/70/100/30/30/30/130/130/100/81/140/130/1070/31/30/50/130/260/30/70/100/90/40/80/40/60/51/410/10/160/10/250/250/25
Most frequent other events
Showing 10 of 549
Most frequent other events
EventCohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort J: Doseage UnknownCohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3
AnaemiaBlood and lymphatic system disorders2/31/33/42/62/63/74/101/30/30/37/134/136/104/86/143/1344/1071/32/32/53/139/260/32/75/102/91/43/81/42/62/514/410/16/161/17/2512/255/25
LeukopeniaBlood and lymphatic system disorders0/30/30/40/62/61/71/100/31/30/30/131/133/104/81/144/1330/1071/31/31/56/1312/260/31/70/101/92/42/81/43/60/514/411/11/160/14/257/256/25
LymphopeniaBlood and lymphatic system disorders0/30/30/40/60/61/70/100/30/30/31/131/131/102/81/143/1320/1072/31/30/54/136/261/31/70/100/93/43/81/42/61/59/411/14/161/17/2510/257/25
NeutropeniaBlood and lymphatic system disorders1/32/32/44/64/63/73/103/30/31/36/134/134/104/89/149/1366/1071/32/34/510/1323/262/33/74/105/92/43/82/46/65/524/411/16/160/118/2522/2520/25
ThrombocytopeniaBlood and lymphatic system disorders1/31/32/42/61/61/71/100/30/30/34/130/134/102/81/145/1340/1071/32/32/54/138/260/33/73/103/91/44/82/42/64/512/411/15/160/15/255/256/25
ChalazionEye disorders0/30/30/40/60/60/70/100/30/30/30/130/130/100/80/140/130/1070/30/30/51/130/261/30/70/100/90/40/80/40/60/50/411/10/160/10/250/250/25
ConstipationGastrointestinal disorders1/31/32/42/61/61/71/100/30/30/30/132/133/104/81/142/1325/1070/31/33/52/133/261/33/71/102/90/40/80/42/62/511/411/19/161/111/257/258/25
DyspepsiaGastrointestinal disorders0/31/31/40/60/60/70/100/30/30/30/131/130/100/82/140/133/1070/31/30/50/130/260/30/72/100/90/40/80/40/60/54/411/12/161/10/251/251/25
AstheniaGeneral disorders0/30/30/40/60/61/70/102/30/30/31/130/131/102/81/141/1318/1070/30/31/50/132/260/32/72/101/90/40/80/40/60/51/410/14/161/15/257/255/25
FatigueGeneral disorders3/32/32/43/63/63/74/101/30/32/33/134/135/104/85/146/1326/1070/32/32/56/139/260/33/74/104/92/44/82/40/60/516/411/16/160/17/258/255/25

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3Total
18 - 64 years old2232135122755266542207122545251201901022181
65 - 84 years old11145452116856875311561412642334422116252222282
85+ years old00000000000000000000000000000010000113
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3Total
Female121334510087549847022617112613343211512129219
Male2133335233565455603137926833512220012131316247
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3Total
Hispanic or Latino010000100001000030101010002110010112018
Not Hispanic or Latino32444763221311106141397315122527991736540115242123420
Unknown or Not Reported000220301101020070100100101000000102228
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Treatment 1Cohort A: Treatment 2Cohort A: Treatment 3Cohort A: Treatment 4Cohort A: Treatment 5Cohort A: Treatment 6Cohort B: Treatment 1Cohort B: Treatment 2Cohort B: Treatment 3Cohort B: Treatment 4Cohort B: Treatment 5Cohort B: Treatment 6Cohort B: Treatment 7Cohort B: Treatment 8Cohort B: Treatment 9Cohort B: Treatment 10Cohort D: Treatment 1Cohort E: Treatment 1Cohort E: Treatment 2Cohort E: Treatment 3Cohort E: Treatment 4Cohort E: Treatment 5Cohort F: Treatment 1Cohort F: Treatment 2Cohort F: Treatment 3Cohort F: Treatment 4Cohort G: Treatment 1Cohort G: Treatment 2Cohort G: Treatment 3Cohort H1Cohort H2Cohort ICohort J1: Treatment 1Cohort J1: Treatment 2Cohort K: Treatment 1Cohort K: Treatment 2Cohort K: Treatment 3Total
American Indian or Alaska Native00000000000000000000000000000000000000
Asian000000000000000000000000100006500054223
Native Hawaiian or Other Pacific Islander00000000000000000000000000000000000000
Black or African American1000112010221022152110502010000050021151
White2344366312101096121184114122034883840034116161819356
More than one race00000000000000000000000000000000000000
Unknown or Not Reported000220201111020080101101101000020122336
08

Study locations

162 sites
  • Local Institution - 102
    Scottsdale, Arizona 85259, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Local Institution - 107
    Little Rock, Arkansas 72205, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Local Institution - 101
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Local Institution - 120
    Chicago, Illinois 60611, United States
  • Robert H Lurie Comprehensive Cancer Center NW Univ
    Chicago, Illinois 60611, United States
  • Local Institution - 113
    Fairway, Kansas 66205, United States
  • University of Kansas Cancer Center
    Fairway, Kansas 66205, United States
  • Local Institution - 106
    Baltimore, Maryland 21201, United States
  • University of Maryland School of Med
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Local Institution - 114
    Boston, Massachusetts 02115, United States
  • Local Institution - 115
    Boston, Massachusetts 02117, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02117, United States
  • Dana-Farber/Mass General Brigham Cancer Care, Inc
    Boston, Massachusetts 02215, United States
  • Local Institution - 110
    Boston, Massachusetts 02215, United States
  • Local Institution - 104
    Ann Arbor, Michigan 48109, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Local Institution - 103
    Detroit, Michigan 48201, United States
  • Local Institution - 140
    Grand Island, Nebraska 68803, United States
  • Local Institution - 141
    Grand Island, Nebraska 68803, United States
  • Local Institution - 137
    Omaha, Nebraska 68114, United States
  • Local Institution - 138
    Omaha, Nebraska 68124, United States
  • Local Institution - 131
    Omaha, Nebraska 68130, United States
  • Local Institution - 139
    Papillion, Nebraska 68046, United States
  • Local Institution - 756
    Cherry Hill, New Jersey 08003, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Local Institution - 108
    Hackensack, New Jersey 07601, United States
  • Local Institution - 122
    Mineola, New York 11501, United States
  • NYU Winthrop Hospital
    Mineola, New York 11501, United States
  • Local Institution - 121
    New York, New York 10016, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai Medical Center
    New York, New York 10029, United States
  • Local Institution - 109
    New York, New York 10029, United States
  • Local Institution - 111
    New York, New York 10065, United States
  • New York Presbyterian Hospital Weil Cornell Medical College
    New York, New York 10065, United States
  • Local Institution - 125
    Rochester, New York 14642, United States
  • University of Rochester Cancer Center
    Rochester, New York 14642, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Local Institution - 112
    Charlotte, North Carolina 28204, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Local Institution - 117
    Cleveland, Ohio 44195, United States
  • Local Institution - 124
    Columbus, Ohio 43210, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Local Institution - 116
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 123
    Greenville, South Carolina 29605, United States
  • Prisma Health Cancer Institute
    Greenville, South Carolina 29605, United States
  • Local Institution - 134
    Memphis, Tennessee 38120, United States
  • Local Institution - 118
    Dallas, Texas 75390, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Huntsman Cancer Institute at the University of Utah
    Salt Lake City, Utah 84112-5550, United States
  • Local Institution - 119
    Salt Lake City, Utah 84112-5550, United States
  • Local Institution - 126
    Seattle, Washington 98109, United States
  • Local Institution - 132
    Tacoma, Washington 98405, United States
  • Local Institution - 854
    Adelaide, South Australia 5000, Australia
  • Local Institution - 852
    Box Hill, Victoria 3128, Australia
  • Local Institution - 904
    Calgary, Alberta T2N 4N2, Canada
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 901
    Vancouver, British Columbia V5Z 1M9, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Local Institution - 902
    Halifax, Nova Scotia B3H 1V7, Canada
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 1V7, Canada
  • Local Institution - 903
    Montreal, Quebec H4A 3J1, Canada
  • McGill University Health Center - Royal Victoria Hospital
    Montreal, Quebec H4A 3J1, Canada
  • CHRU Hopital Claude Huriez
    Lile Cedax, 59037, France
  • Local Institution - 704
    Lile Cedax, 59037, France
  • CHU Bordeaux
    Pessac, 33604, France
  • Local Institution - 701
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Local Institution - 703
    Pierre-Bénite, 69495, France
  • CHU La Miletrie
    Poitiers, 86021, France
  • Local Institution - 702
    Poitiers, 86021, France
  • Local Institution - 605
    Dresden, 01307, Germany
  • Medizinische Kinik und Poliklinik I
    Dresden, 01307, Germany
  • Local Institution - 603
    Düsseldorf, 40225, Germany
  • Universitaetsklinikum Duesseldorf
    Düsseldorf, 40225, Germany
  • Local Institution - 604
    Hamburg, 20246, Germany
  • Universitaetsklinik Hamburg - Eppendorf
    Hamburg, 20246, Germany
  • Local Institution - 602
    Heidelberg, 69120, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Local Institution - 601
    Tübingen, 72076, Germany
  • UKT Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
  • Local Institution - 606
    Würzburg, 97080, Germany
  • Universitaets-klinikum Wuerzburg
    Würzburg, 97080, Germany
  • Local Institution - 751
    Jerusalem, Jerusalem 91031, Israel
  • Local Institution - 755
    Tel Aviv, 64239, Israel
  • Local Institution - 754
    Tel Litwinsky, 52620, Israel
  • Local Institution - 307
    Meldola, 47014, Italy
  • I.R.C.C.S. Policlinico San Matteo - Universita di Pavia
    Pavia, 27100, Italy
  • Local Institution - 305
    Pavia, 27100, Italy
  • Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova
    Reggio Emilia, 42100, Italy
  • Local Institution - 302
    Reggio Emilia, 42100, Italy
  • Local Institution - 303
    Rome, 00161, Italy
  • Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma - Centro di Ematologia
    Rome, 00161, Italy
  • Local Institution - 301
    Torino, 10126, Italy
  • Osp. S.Giovanni Battista Le Molinette
    Torino, 10126, Italy

Showing the first 100 of 162 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M, Ortiz M, Maciag P, Peluso T, Parekh S, van de Donk NWCJ, Lonial S, Thakurta A. Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma. Cell Rep Med. 2024 Jun 18;5(6):101571. doi: 10.1016/j.xcrm.2024.101571. Epub 2024 May 21. PubMed 38776914 ↗
  • Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022 Nov;9(11):e822-e832. doi: 10.1016/S2352-3026(22)00290-3. Epub 2022 Oct 6. PubMed 36209764 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in May 2024, 90 months.

Results were first posted in Mar 2026, 1 year 10 months after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 90 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2016
First posted
May 16, 2016
StartActual
Oct 14, 2016
Primary completionActual
May 9, 2024
CompletionEst.
Jul 28, 2028
Results first posted
Mar 20, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02773030
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 16, 2016
Start date
Oct 14, 2016
Primary completion
May 9, 2024
Completion
Jul 28, 2028 (estimated)
Results posted
Mar 20, 2026
Last update
Mar 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iberdomide · Daratumumab

Start the discussion